GLTO Insider Trading
Insider Ownership Percentage: 11.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $8,979.03
Galecto Share Price & Price History
Current Price: $3.07
Price Change: ▼ Price Decrease of -0.035 (-1.13%)
As of 04/1/2025 03:03 PM ET
Galecto Insider Trading History
Galecto Institutional Trading History
Data available starting January 2016
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More on Galecto
Volume
23,120 shs
Average Volume
74,311 shs
Market Capitalization
$4.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.18
Who are the company insiders with the largest holdings of Galecto?